Next Article in Journal
Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2—An In Vitro Study
Previous Article in Journal
Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles
Open AccessReview

Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review

Duke Cancer Institute, Duke University Health System, Durham, NC 27710, USA
The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London SW3 6JJ, UK
Department of Medical Oncology, Institute Bergonié, 33000 Bordeaux, France
Immune Design Corporation, San Francisco, CA 94080, USA
ICON Epidemiology, ICON plc, Abingdon OX14 4RY, UK
ICON Epidemiology, ICON plc, Vancouver, BC V6B 1P1, Canada
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
Siteman Cancer Center, St. Louis, MO 63110, USA
Author to whom correspondence should be addressed.
Cancers 2018, 10(11), 417;
Received: 15 October 2018 / Revised: 29 October 2018 / Accepted: 30 October 2018 / Published: 1 November 2018
Synovial sarcoma (SS) is an aggressive malignancy which accounts for approximately 5–10% of all soft-tissue sarcomas. SS has pathologic and genomic characteristics that define it as a distinct subtype of soft tissue sarcoma (STS). STS subtypes continue to be recognized as distinct entities with specific characteristics, including differential chemo-sensitivity. The objective of this study was to conduct a descriptive review of current data on survival outcomes of systemic anti-cancer therapy specific to SS. A systematic literature review was conducted, using a custom search strategy to search EMBASE, Medline and CENTRAL for clinical trials and observational studies reporting overall survival (OS), progression-free survival (PFS) and/or response for cohorts of at least 50 SS patients. We identified 28 studies meeting these criteria, 25 of which were retrospective studies. Only three prospective studies were identified. Survival reports varied widely between studies based on the population, in particular on the disease stage, and reporting was heterogeneous in terms of the time points reported on. For patients with localized disease, reports of five-year PFS ranged from 26% to 80.7% and five-year OS from 40% to 90.7%, whereas five-year OS for patients with metastatic disease was very low at around 10%; and in one case, 0% was reported. Only four of the included publications reported outcomes by type of systemic anti-cancer therapy received. Our study draws attention to the fact that additional prospective studies to better define the most appropriate treatment for SS in all stages and lines of therapy are still needed. View Full-Text
Keywords: synovial sarcoma; survival; chemotherapy; systemic anti-cancer therapy; systematic review synovial sarcoma; survival; chemotherapy; systemic anti-cancer therapy; systematic review
Show Figures

Figure 1

MDPI and ACS Style

Riedel, R.F.; Jones, R.L.; Italiano, A.; Bohac, C.; Thompson, J.C.; Mueller, K.; Khan, Z.; Pollack, S.M.; Van Tine, B.A. Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. Cancers 2018, 10, 417.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop